STATEMENT OF NEED
Prostate cancer is the most common tumor type affecting men in the United States. An estimated 268,490 new cases are diagnosed annually, and 34,500 people die of the disease (ACS, 2022). Typically, androgen deprivation therapy (ADT) is administered for progressive disease. However, castration resistance or unresponsiveness to ADT or antiandrogens frequently develop over time. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with limited effective treatment options. Metastatic CRPC is the primary cause of prostate cancer-related mortality and is associated with a median overall survival of less than 2 years (Seyegh et al, 2022). Therefore, it is critical for oncology nurses and others involved in the care of patients with prostate cancer to maintain up-to-date knowledge about CRPC therapies and supportive care. In this activity, Kathy Burns, MSN, ANP, OCN®, will discuss various topics relevant to the treatment of metastatic CRPC, including diagnosis, staging, and the latest clinical trial results. She will also highlight the management of drug interactions and adverse events related to novel therapies.
Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC).
Upon completion of this activity, participants should be able to:
Kathleen D. Burns, MSN, AGACNP-BC, OCN®
Division of Genitourinary Medical Oncology
City of Hope Comprehensive Cancer Center
There is no fee to participate in or claim NCPD credit for this activity.
NURSING CONTINUING PROFESSIONAL DEVELOPMENT
i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.9 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1.0 ILNA point toward:
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of a NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Kathleen D. Burns, MSN, AGACNP-BC, OCN®, discloses that she has served on an advisory board or panel for AVEO, Eisai, and Exelixis, and that she has served on a speaker’s bureau for Amgen, Astellas, AstraZeneca, AVEO, Exelixis, Pfizer, and Sanofi Genzyme.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
Technology requirements for virtual CME | NCPD | CPE activities
For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CE activities, include access to system requirements:
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by independent educational grants from Sanofi, Merck, and AstraZeneca.
Aggregate participant data will be shared with commercial supporters of this activity.